Double-blind Comparative Study of TAK-875.

Trial Profile

Double-blind Comparative Study of TAK-875.

Phase of Trial: Phase III

Latest Information Update: 28 Feb 2018

At a glance

  • Drugs Fasiglifam (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Sponsors Takeda
  • Most Recent Events

    • 28 Feb 2018 Results of an integrated pooled analysis (n=9139) assessing the hepatic safety of fasiglifam from the data of 15 double-blind studies from both global and Japanese development programs (six phase II and nine phase III) including this study, published in the Drug Safety Journal.
    • 10 Jun 2017 Biomarkers information updated
    • 24 Sep 2013 Primary endpoint 'Proportion-of-glycosylated-haemoglobin' has been met.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top